Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine
NCT ID: NCT06291779
Last Updated: 2024-03-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
120 participants
OBSERVATIONAL
2022-11-30
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pancreatic Cancer Detection Consortium
NCT06388967
Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer
NCT05596370
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
NCT02072616
Role of Perfusion CT in Pancreatic Cancer
NCT01703650
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
NCT06166147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Through quantitative analysis of hypoxanthine and xanthine in the urine of normal people and pancreatic cancer patients, we plan to confirm the possibility of diagnosing pancreatic cancer using reagents for analyzing purine metabolites.
* Early diagnosis of pancreatic cancer is a key determinant of cure and survival rates, and impact on all aspects of cancer, including rate of progression, treatment, and prognosis.
* This study could change the paradigm of pancreatic cancer screening by evaluating the stability and accuracy of urinary purine metabolite analysis reagents.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pancreatic cancer group
scheduled for curative surgery for pancreatic cancer
Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
* Collect urine from the patient to measure urinary hypoxia, xanthine concentration.
* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).
* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.
* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample.
Control group
group included healthy individuals as well as patients with benign diseases
Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
* Collect urine from the patient to measure urinary hypoxia, xanthine concentration.
* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).
* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.
* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
* Collect urine from the patient to measure urinary hypoxia, xanthine concentration.
* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).
* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.
* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with resectable pancreatic cancer at the time of surgery (Including borderline resectable pancreatic cancer at the time of diagnosis or Locally advanced pancreatic cancer after chemotherapy or radiation therapy)
* Patients without invasion of adjacent organs other than the left adrenal gland and mesocolon
* Patients with informed consent
Exclusion Criteria
* Patient with Inflammatory disease(e.g. severe pancreatitis, cholangitis)
* Patients with underlying diseases at high risk of general anesthesia
* Other subject whom the investigator deems inappropriate
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Bundang Hospital
OTHER
Ho-Seong Han
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ho-Seong Han
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ho-Seong Han, M.D. Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Bundang Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ho-Seong Han
Seongnam-si, Gyeonggi-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta. 2009 Aug 19;648(1):98-104. doi: 10.1016/j.aca.2009.06.033. Epub 2009 Jun 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E-2211-792-350 (local IRB)
Identifier Type: OTHER
Identifier Source: secondary_id
SNUBH-GS- HBP5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.